User login
Key clinical point: Bimekizumab demonstrated consistent safety and sustained efficacy for up to 2 years in patients with psoriatic arthritis (PsA) who were biologic-naive or inadequately responsive to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: From weeks 52 to 104, the incidence of treatment emergent adverse events (TEAE) was consistent with previous studies, with no new safety signals. SARS-CoV2 infection (18.6 per 100 patient-years) was the most common TEAE. Approximately 50% biologic-naive and TNFi-IR patients maintained a ≥50% improvement in the American College of Rheumatology response.
Study details: This open-label extension (BE-VITAL) of two phase 3 trials included biologic-naive (n = 852) and TNFi-IR (n = 400) patients with PsA who were randomly assigned to receive bimekizumab, placebo with crossover to bimekizumab at week 16, or adalimumab followed by bimekizumab at week 52.
Disclosures: This study was sponsored by UCB Pharma. Five authors declared being employees or shareholders of UCB Pharma. LC Coates declared being an editorial board member of Rheumatology and Therapy. Other authors declared having ties with various sources, including UCB.
Source: Mease PJ, Merola JF, Tanaka Y, et al. Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatol Ther. 2024 (Aug 31). doi: 10.1007/s40744-024-00708-8 Source
Key clinical point: Bimekizumab demonstrated consistent safety and sustained efficacy for up to 2 years in patients with psoriatic arthritis (PsA) who were biologic-naive or inadequately responsive to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: From weeks 52 to 104, the incidence of treatment emergent adverse events (TEAE) was consistent with previous studies, with no new safety signals. SARS-CoV2 infection (18.6 per 100 patient-years) was the most common TEAE. Approximately 50% biologic-naive and TNFi-IR patients maintained a ≥50% improvement in the American College of Rheumatology response.
Study details: This open-label extension (BE-VITAL) of two phase 3 trials included biologic-naive (n = 852) and TNFi-IR (n = 400) patients with PsA who were randomly assigned to receive bimekizumab, placebo with crossover to bimekizumab at week 16, or adalimumab followed by bimekizumab at week 52.
Disclosures: This study was sponsored by UCB Pharma. Five authors declared being employees or shareholders of UCB Pharma. LC Coates declared being an editorial board member of Rheumatology and Therapy. Other authors declared having ties with various sources, including UCB.
Source: Mease PJ, Merola JF, Tanaka Y, et al. Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatol Ther. 2024 (Aug 31). doi: 10.1007/s40744-024-00708-8 Source
Key clinical point: Bimekizumab demonstrated consistent safety and sustained efficacy for up to 2 years in patients with psoriatic arthritis (PsA) who were biologic-naive or inadequately responsive to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: From weeks 52 to 104, the incidence of treatment emergent adverse events (TEAE) was consistent with previous studies, with no new safety signals. SARS-CoV2 infection (18.6 per 100 patient-years) was the most common TEAE. Approximately 50% biologic-naive and TNFi-IR patients maintained a ≥50% improvement in the American College of Rheumatology response.
Study details: This open-label extension (BE-VITAL) of two phase 3 trials included biologic-naive (n = 852) and TNFi-IR (n = 400) patients with PsA who were randomly assigned to receive bimekizumab, placebo with crossover to bimekizumab at week 16, or adalimumab followed by bimekizumab at week 52.
Disclosures: This study was sponsored by UCB Pharma. Five authors declared being employees or shareholders of UCB Pharma. LC Coates declared being an editorial board member of Rheumatology and Therapy. Other authors declared having ties with various sources, including UCB.
Source: Mease PJ, Merola JF, Tanaka Y, et al. Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatol Ther. 2024 (Aug 31). doi: 10.1007/s40744-024-00708-8 Source